Efficacy and Safety of Glofitamab in the Real-World Treatment of Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma (ChiCTR) - Sep 16, 2026 - P4 | N=20 | Not yet recruiting | Sponsor: Henan Cancer Hospital; Henan Cancer Hospital
HEOR • New P4 trial • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin's Lymphoma • Oncology
|